If public opinion around pricing turns sour among scientists, policymakers, or the public, the financial risks are real.
#DrugPricing #PublicSentiment #BusinessEthics
If public opinion around pricing turns sour among scientists, policymakers, or the public, the financial risks are real.
#DrugPricing #PublicSentiment #BusinessEthics
Sometimes, in the short run. But not always—and it may hurt in the long term, especially when the right people are watching.
🧪📢⚖️
Sometimes, in the short run. But not always—and it may hurt in the long term, especially when the right people are watching.
🧪📢⚖️
We found that firms facing less negative sentiment over time outperformed those with more public backlash.
Higher short-term returns don’t guarantee long-term success.
📉⏳
We found that firms facing less negative sentiment over time outperformed those with more public backlash.
Higher short-term returns don’t guarantee long-term success.
📉⏳
When scientific or political news outlets express negative sentiment, firm performance drops.
These communities hold reputational and regulatory power—and their criticism can sting.
#StakeholderPower
When scientific or political news outlets express negative sentiment, firm performance drops.
These communities hold reputational and regulatory power—and their criticism can sting.
#StakeholderPower
When business, finance, and legal news outlets or Reddit users react negatively to drug prices, firm performance often goes up.
Why? These audiences may interpret it as a bold, profit-maximising move.
#ShortTermGains
When business, finance, and legal news outlets or Reddit users react negatively to drug prices, firm performance often goes up.
Why? These audiences may interpret it as a bold, profit-maximising move.
#ShortTermGains
The goal? To see whether public outrage has financial consequences.
The goal? To see whether public outrage has financial consequences.